secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2026-02-18T23:59:59+00:00
Accession:  0001213900-26-017641
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay Diagnostics enrolls 545 patients in SYMON™ II study, exceeds expectations
--------------------------------------------------------------------------------

- Enrolled 545 of 750 target patients in SYMON™ II multicenter IL-6 monitoring study, exceeding initial expectations.
- Completed monoclonal and polyclonal antibody production, providing capacity for >10 million test cartridges.
- Manufacturing readiness includes cartridge characterization for U.S. commercial production and ongoing fabrication for FDA submission.
- Company transitions focus to data analysis, regulatory engagement, and commercialization preparedness in 2026.
- Technology transfer activities progress without single point of failure, mitigating scale-up risk.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390026017641/0001213900-26-017641-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390026017641/ea0277474-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-017641

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer